Osimertinib in NSCLC With Atypical -Activating Mutations: A Retrospective Multicenter Study.

INTRODUCTION

mutations drive a subset of NSCLC. Patients harboring the common mutations, deletion of exon 19 and L858R, respond well to osimertinib, a third-generation tyrosine kinase inhibitor. Nevertheless, the effect of osimertinib on NSCLC with atypical mutations is not well described. This multicenter retrospective study evaluates the efficacy of osimertinib among patients with NSCLC harboring atypical mutations.

METHODS

Patients with metastatic NSCLC treated with osimertinib, harboring at least one atypical mutation, excluding concurrent deletion of exon 19, L858R, or T790M mutations, from six U.S. academic cancer centers were included. Baseline clinical characteristics were collected. The primary end point was the time to treatment discontinuation (TTD) of osimertinib. Objective response rate by the Response Evaluation Criteria in Solid Tumors version 1.1 was also assessed.

RESULTS

A total of 50 patients with NSCLC with uncommon mutations were identified. The most frequent mutations were L861Q (40%, n = 18), G719X (28%, n = 14), and exon 20 insertion (14%, n = 7). The median TTD of osimertinib was 9.7 months (95% confidence interval [CI]: 6.5-12.9 mo) overall and 10.7 months (95% CI: 3.2-18.1 mo) in the first-line setting (n = 20). The objective response rate was 31.7% (95% CI: 18.1%-48.1%) overall and 41.2% (95% CI: 18.4%-67.1%) in the first-line setting. The median TTD varied among patients with L861Q (17.2 mo), G719X (7.8 mo), and exon 20 insertion (1.5 mo) mutations.

CONCLUSIONS

Osimertinib has activity in patients with NSCLC harboring atypical mutations. Osimertinib activity differs by the type of atypical -activating mutation.